Targeted RNA Sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Exome Sequencing, Enrichment Sequencing, Amplicon Sequencing, Others), By Application (Cancer Gene Sequencing, Inherited Disease Screening, Drug Development, Forensic Genomics, 16S ribosomal RNA (rRNA) Sequencing), Regional Insights and Forecast to 2035

Targeted RNA Sequencing Market Overview

Targeted RNA Sequencing Market size is anticipated to be worth USD 5268.36 million in 2026, projected to reach USD 9338.97 million by 2035 at a 6.57% CAGR.

The Targeted RNA Sequencing market is experiencing significant growth due to increasing adoption of precision medicine, biomarker discovery, and transcriptome analysis in clinical diagnostics and life sciences research. Targeted RNA sequencing enables highly accurate detection of gene expression, fusion transcripts, splice variants, and disease-associated biomarkers while reducing sequencing costs and analysis time. More than 68% of oncology genomic studies now incorporate targeted RNA sequencing for molecular profiling and therapeutic decision-making. Rising investments in personalized medicine, expanding next-generation sequencing (NGS) infrastructure, and increasing demand for companion diagnostics continue driving market expansion. Continuous technological advancements in sequencing chemistry, automation, and bioinformatics are further improving sequencing accuracy, throughput, and clinical applicability.

The United States represents one of the largest markets for Targeted RNA Sequencing owing to advanced genomic research infrastructure and widespread adoption of precision medicine. More than 3,500 clinical laboratories and research institutions utilize next-generation sequencing technologies for disease diagnosis and biomedical research. Approximately 72% of major cancer centers employ RNA sequencing as part of molecular profiling programs. Growing government funding for genomic medicine, increasing pharmaceutical investment in biomarker-based drug development, and expanding clinical adoption of companion diagnostics continue supporting market growth. The presence of leading sequencing technology providers and research organizations further strengthens the Targeted RNA Sequencing market across the United States.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 69% of precision oncology programs utilize targeted RNA sequencing, while approximately 61% of genomic laboratories have expanded NGS-based transcriptome testing capabilities.
• Major Market Restraint: Nearly 43% of laboratories report high sequencing workflow costs, while approximately 38% identify complex bioinformatics analysis as a major implementation challenge.
• Emerging Trends: Around 57% of newly introduced sequencing platforms integrate AI-assisted bioinformatics, while approximately 49% support automated targeted RNA library preparation.
• Regional Leadership: North America accounts for approximately 39% of global market demand, Europe contributes nearly 28%, while Asia-Pacific represents approximately 26% of worldwide targeted RNA sequencing activity.
• Competitive Landscape: Nearly 71% of advanced targeted RNA sequencing platforms are supplied by leading global genomics companies investing in next-generation sequencing innovation.
• Market Segmentation: Cancer gene sequencing accounts for approximately 46% of market demand, drug development represents nearly 22%, while inherited disease screening contributes approximately 15%.
• Recent Development: Nearly 54% of newly introduced targeted RNA sequencing solutions emphasize higher sequencing accuracy, automation, and faster clinical workflow integration.

Targeted RNA Sequencing Market Latest Trends

The Targeted RNA Sequencing market is undergoing rapid transformation through continuous advancements in next-generation sequencing technologies, artificial intelligence, and precision medicine. Automated library preparation systems, cloud-based bioinformatics platforms, and AI-assisted data interpretation are improving workflow efficiency and reducing turnaround times. More than 60% of newly developed sequencing platforms now support integrated sample preparation and advanced transcriptome analysis. Targeted RNA sequencing is increasingly applied in cancer diagnostics for fusion gene detection, biomarker discovery, and treatment response monitoring. Pharmaceutical companies are expanding its use in drug development, while research institutions increasingly utilize targeted sequencing for inherited disease screening and forensic genomics. Multiplex sequencing panels, enhanced sequencing chemistry, and improved computational pipelines continue increasing analytical sensitivity and reproducibility. Growing investments in molecular diagnostics, clinical genomics, and personalized healthcare are expected to further accelerate global adoption of targeted RNA sequencing technologies.

Targeted RNA Sequencing Market Dynamics

DRIVER

"Growing adoption of precision medicine and molecular diagnostics."

The Targeted RNA Sequencing market is primarily driven by the rapid expansion of precision medicine and molecular diagnostics across healthcare systems worldwide. More than 68% of oncology research programs now utilize targeted RNA sequencing for identifying gene fusions, expression profiles, and actionable biomarkers that support personalized treatment decisions. Approximately 62% of pharmaceutical companies integrate RNA sequencing into biomarker-driven clinical trials and drug discovery programs. Increasing prevalence of cancer, rare genetic disorders, and infectious diseases has accelerated the demand for highly accurate transcriptomic analysis. Government investments in genomic medicine, expanding next-generation sequencing infrastructure, and continuous improvements in sequencing chemistry are further strengthening adoption across clinical laboratories, academic research centers, and biotechnology organizations.

RESTRAINT

"High implementation costs and complex bioinformatics requirements."

The Targeted RNA Sequencing market faces significant restraints due to the substantial investment required for sequencing instruments, workflow automation, reagents, and computational infrastructure. Nearly 43% of diagnostic laboratories identify equipment acquisition and operational expenses as major barriers to implementation. Approximately 38% of genomic research institutions report challenges associated with bioinformatics expertise, data storage, and interpretation of large sequencing datasets. Sample preparation complexity, quality control requirements, and regulatory compliance further increase laboratory operating costs. Limited reimbursement policies in several healthcare systems and shortages of skilled genomics professionals continue restricting widespread adoption, particularly in emerging economies and smaller diagnostic facilities.

OPPORTUNITY

"Expansion of companion diagnostics and clinical genomic testing."

The increasing use of companion diagnostics and personalized therapeutics presents substantial opportunities for the Targeted RNA Sequencing market. More than 57% of newly developed molecular diagnostic assays now incorporate targeted RNA analysis to support biomarker identification and treatment selection. Pharmaceutical companies are expanding collaborations with sequencing technology providers to accelerate targeted drug development and clinical trial enrollment. Growing investments in liquid biopsy research, infectious disease surveillance, inherited disease screening, and population genomics are creating additional demand for advanced RNA sequencing platforms. Expanding healthcare infrastructure throughout Asia-Pacific and other emerging markets is also increasing opportunities for sequencing technology manufacturers and clinical testing laboratories.

CHALLENGE

"Managing large-scale genomic data while ensuring clinical accuracy."

A major challenge for the Targeted RNA Sequencing market is processing and interpreting increasingly complex genomic datasets while maintaining high analytical accuracy and regulatory compliance. Approximately 46% of sequencing laboratories continue investing in artificial intelligence, cloud computing, and automated bioinformatics pipelines to improve data interpretation and reporting efficiency. Variability in sample quality, sequencing depth, transcript abundance, and laboratory protocols can affect reproducibility across clinical settings. Standardizing workflows, validating sequencing panels, protecting sensitive patient genomic information, and complying with evolving regulatory requirements require continuous investment in quality management systems, computational infrastructure, and workforce training, creating ongoing operational challenges for market participants.

Targeted RNA Sequencing Market Segmentation

The Targeted RNA Sequencing market is segmented by sequencing technology and application to support diverse clinical diagnostics, pharmaceutical research, and genomic discovery programs. Continuous advances in sequencing chemistry, bioinformatics software, automation, and transcriptomic analysis are improving sensitivity, workflow efficiency, and clinical utility across all market segments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

By Type

Exome Sequencing: Exome Sequencing accounts for approximately 33% of the market due to its broad application in identifying coding-region variants, disease-associated mutations, and clinically relevant biomarkers used in precision medicine and translational research.

Enrichment Sequencing: Enrichment Sequencing represents approximately 27% of market demand because it enables highly targeted analysis of selected genomic regions, improves sequencing efficiency, and reduces overall workflow costs for clinical and research applications.

Amplicon Sequencing: Amplicon Sequencing contributes approximately 24% of the global market through its rapid, cost-effective detection of specific gene targets, fusion transcripts, and mutation panels widely used in oncology and infectious disease diagnostics.

Others: Other targeted RNA sequencing technologies account for approximately 16% of the market, including customized targeted panels and emerging transcriptomic sequencing methods designed for specialized clinical and research applications.

By Application

Cancer Gene Sequencing: Cancer Gene Sequencing accounts for approximately 46% of total market demand due to increasing use in precision oncology, biomarker discovery, gene fusion detection, and treatment response monitoring.

Inherited Disease Screening: Inherited Disease Screening represents approximately 15% of the market, supported by growing adoption of genomic testing for rare diseases, hereditary disorders, and prenatal diagnostic applications.

Drug Development: Drug Development contributes approximately 22% of market demand as pharmaceutical and biotechnology companies increasingly utilize targeted RNA sequencing for biomarker validation, target identification, and clinical trial optimization.

Forensic Genomics: Forensic Genomics accounts for approximately 9% of the market by supporting human identification, biological evidence analysis, and advanced forensic investigations using transcriptomic technologies.

16S ribosomal RNA (rRNA) Sequencing: 16S ribosomal RNA (rRNA) Sequencing represents approximately 8% of market demand due to its widespread application in microbial identification, microbiome profiling, infectious disease research, and environmental genomics.

Targeted RNA Sequencing Market Regional Outlook

The Targeted RNA Sequencing market demonstrates strong regional growth driven by increasing investments in precision medicine, genomic research, and molecular diagnostics. North America accounts for approximately 39% of global demand due to its advanced sequencing infrastructure and widespread adoption of personalized healthcare. Europe contributes nearly 28% through extensive biomedical research and clinical genomics programs, while Asia-Pacific represents approximately 26% owing to expanding healthcare investments and growing genomics initiatives. The Middle East & Africa accounts for approximately 7% of market demand, supported by improving healthcare infrastructure and increasing adoption of molecular diagnostic technologies.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

north america

North America holds approximately 39% of the global Targeted RNA Sequencing market due to its highly developed healthcare infrastructure, advanced genomic research institutions, and widespread implementation of precision medicine. The United States leads regional adoption with more than 3,500 genomic laboratories and research centers utilizing next-generation sequencing technologies. Increasing investments in oncology research, companion diagnostics, and rare disease studies continue driving demand for targeted RNA sequencing platforms.

Major biotechnology companies, pharmaceutical manufacturers, and academic institutions continue expanding sequencing capabilities through artificial intelligence, cloud-based bioinformatics, and automated laboratory workflows. Growing clinical adoption of RNA sequencing for cancer diagnosis, inherited disease screening, and biomarker discovery further strengthens regional leadership. Continuous government funding for genomic medicine and personalized healthcare initiatives supports sustained market expansion across North America.

europe

Europe accounts for approximately 28% of the global Targeted RNA Sequencing market, supported by extensive biomedical research, advanced healthcare systems, and strong government investment in genomics. Germany, the United Kingdom, France, Italy, and the Netherlands remain leading contributors through expanding molecular diagnostic laboratories and precision oncology programs. Increasing adoption of transcriptomic technologies for clinical diagnostics and pharmaceutical research continues driving regional market growth.

Collaborative research projects between universities, biotechnology companies, and healthcare organizations are accelerating innovation in RNA sequencing applications. Regulatory support for personalized medicine, increasing availability of sequencing reimbursement, and expanding pharmaceutical research activities continue encouraging the adoption of advanced targeted RNA sequencing technologies across Europe.

asia-pacific

Asia-Pacific represents approximately 26% of the global Targeted RNA Sequencing market and continues experiencing rapid growth due to increasing healthcare expenditure, expanding genomic research, and rising cancer incidence. China, Japan, India, South Korea, and Australia are investing significantly in precision medicine, national genome projects, and advanced molecular diagnostic infrastructure. Growing biotechnology industries and increasing adoption of next-generation sequencing technologies further support regional expansion.

Governments throughout the region are strengthening genomic medicine initiatives while healthcare providers continue modernizing clinical laboratories with automated sequencing platforms and advanced bioinformatics systems. Rising pharmaceutical research activities, expanding clinical trials, and increasing awareness of personalized medicine continue creating significant opportunities for targeted RNA sequencing technology providers across Asia-Pacific.

middle east & africa

The Middle East & Africa accounts for approximately 7% of the global Targeted RNA Sequencing market, supported by improving healthcare infrastructure and growing investment in molecular diagnostics. Countries including Saudi Arabia, the United Arab Emirates, and South Africa are expanding genomic research facilities and introducing precision medicine programs to improve disease diagnosis and patient outcomes. Increasing collaborations with international genomics companies continue strengthening regional capabilities.

Academic institutions, government healthcare organizations, and private diagnostic laboratories are investing in next-generation sequencing technologies to enhance cancer research, inherited disease screening, and infectious disease surveillance. Expanding healthcare modernization initiatives, growing awareness of genomic medicine, and increasing research funding are expected to support long-term market development throughout the Middle East & Africa.

List of Top Targeted RNA Sequencing Companies

• Illumina, Inc.
• F. Hoffmann-La Roche AG
• Qiagen
• Thermo Fisher Scientific, Inc.
• Oxford Nanopore Technologies
• Genenexus

Top Two Companies with Highest  Share

• Illumina, Inc.: Illumina, Inc. is the global leader in next-generation sequencing technologies, providing comprehensive targeted RNA sequencing platforms, sequencing reagents, and advanced bioinformatics solutions for clinical diagnostics and genomic research.
• Thermo Fisher Scientific, Inc.: Thermo Fisher Scientific, Inc. is one of the leading providers of molecular biology instruments, targeted sequencing workflows, and integrated genomic analysis solutions supporting precision medicine, oncology research, and pharmaceutical development worldwide.

Investment Analysis and Opportunities

The Targeted RNA Sequencing market is attracting substantial investments due to the rapid expansion of precision medicine, companion diagnostics, and next-generation sequencing technologies. More than 62% of biotechnology companies have increased investments in transcriptomic research to accelerate biomarker discovery and targeted therapy development. North America accounts for approximately 39% of global demand, making it a major destination for research laboratories, sequencing platform manufacturers, and pharmaceutical collaborations. Investments are focused on high-throughput sequencing instruments, automated library preparation systems, artificial intelligence-driven bioinformatics platforms, and cloud-based genomic data management. Government funding for national genome initiatives, increasing clinical adoption of molecular diagnostics, and growing pharmaceutical research continue creating favorable opportunities for technology providers, diagnostic laboratories, and sequencing service companies operating in the Targeted RNA Sequencing market.

Emerging opportunities are expanding through personalized medicine, oncology research, inherited disease diagnostics, microbiome analysis, and infectious disease surveillance. Approximately 46% of sequencing demand originates from cancer gene sequencing, while drug development programs continue increasing their use of transcriptomic technologies for target identification and clinical trial optimization. Manufacturers are investing in multiplex sequencing panels, portable sequencing platforms, advanced reagent chemistry, and integrated data analysis software to improve laboratory efficiency and analytical accuracy. Strategic partnerships between pharmaceutical companies, academic research institutes, healthcare providers, and sequencing technology developers continue accelerating innovation. Expanding healthcare infrastructure throughout Asia-Pacific and increasing adoption of genomic medicine in emerging economies are expected to generate significant long-term investment opportunities across the global Targeted RNA Sequencing market.

New Product Development

Manufacturers are continuously introducing advanced targeted RNA sequencing solutions with improved sequencing accuracy, faster turnaround time, and simplified laboratory workflows. More than 58% of newly launched sequencing platforms feature automated sample preparation, enhanced library construction technologies, and artificial intelligence-assisted bioinformatics analysis. Multiplex sequencing panels capable of simultaneously analyzing hundreds of RNA targets are becoming increasingly common in oncology diagnostics and pharmaceutical research. Companies are also developing high-sensitivity assays for detecting low-abundance transcripts, gene fusions, splice variants, and rare biomarkers, improving clinical decision-making and personalized treatment planning.

Innovation is also focused on portable sequencing platforms, cloud-based genomic data management, integrated software solutions, and automated quality control systems. Advanced sequencing chemistries are improving read accuracy, reproducibility, and workflow efficiency while reducing reagent consumption and processing time. Manufacturers continue investing in companion diagnostic assays, liquid biopsy applications, and transcriptome profiling technologies to expand clinical utility. These product developments strengthen the adoption of targeted RNA sequencing across cancer research, inherited disease screening, drug discovery, forensic genomics, and microbiome analysis while supporting the growing demand for precision medicine worldwide.

Five Recent Developments (2023-2025)

• 2023: Illumina, Inc. expanded its next-generation sequencing portfolio by enhancing RNA sequencing workflows with improved automation, higher throughput, and advanced bioinformatics integration for clinical and research applications.
• 2023: Thermo Fisher Scientific, Inc. introduced updated targeted sequencing solutions featuring enhanced multiplex capabilities and streamlined library preparation to improve molecular diagnostic workflows.
• 2024: F. Hoffmann-La Roche AG strengthened its precision diagnostics portfolio by expanding genomic testing capabilities supporting companion diagnostics and oncology biomarker analysis.
• 2024: Oxford Nanopore Technologies advanced its nanopore sequencing platform with improved RNA sequencing accuracy, longer read capabilities, and expanded transcriptomic research applications.
• 2025: Leading targeted RNA sequencing companies continued investing in artificial intelligence-driven bioinformatics, cloud-based genomic analysis, and automated sequencing workflows to improve clinical adoption and laboratory efficiency.

Report Coverage of Targeted RNA Sequencing Market

This report provides a comprehensive analysis of the global Targeted RNA Sequencing market by evaluating technological advancements, market trends, competitive dynamics, regional developments, and emerging opportunities across clinical diagnostics and life sciences research. The study covers sequencing technologies including Exome Sequencing, Enrichment Sequencing, Amplicon Sequencing, and other targeted sequencing methods while assessing applications across cancer gene sequencing, inherited disease screening, drug development, forensic genomics, and 16S ribosomal RNA (rRNA) sequencing. It also examines market drivers, restraints, opportunities, and challenges influencing adoption, together with developments in sequencing chemistry, workflow automation, artificial intelligence, and bioinformatics platforms that continue improving analytical accuracy and laboratory efficiency.

The report further profiles leading companies including Illumina, Inc., F. Hoffmann-La Roche AG, Qiagen, Thermo Fisher Scientific, Inc., Oxford Nanopore Technologies, and Genenexus. It includes detailed investment analysis, product innovation trends, competitive benchmarking, regional outlook, and five significant developments recorded during 2023-2025. The study evaluates research collaborations, pharmaceutical partnerships, regulatory developments, precision medicine initiatives, and genomic infrastructure expansion across north america, europe, asia-pacific, and middle east & africa. It serves as a valuable strategic resource for biotechnology companies, clinical laboratories, pharmaceutical manufacturers, academic institutions, healthcare providers, investors, and business decision-makers seeking reliable insights into technological progress, application trends, and future opportunities within the global Targeted RNA Sequencing market while excluding revenue and CAGR analysis.

Targeted RNA Sequencing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5268.36 Billion in 2026
Market Size Value By	USD 9338.97 Billion by 2035
Growth Rate	CAGR of 6.57% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Exome Sequencing Enrichment Sequencing Amplicon Sequencing Others By Application : Cancer Gene Sequencing Inherited Disease Screening Drug Development Forensic Genomics 16S ribosomal RNA (rRNA) Sequencing
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample